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Abstract: A complete understanding of the molecular mechanisms leading to HIV-associated insulin 
resistance remains elusive. Complex interrelationships between genetic predisposition, disease-related 
body  changes  and  multidrug  therapy  all  contribute  to  alterations  in  glucose  homeostasis.  These 
abnormalities can be differentiated between acute and reversible changes directly induced by HAART 
medications and more chronic and less reversible changes due to the development of lipodystrophy and 
hyperlipidemia. Implicated pathways include changes in adipokine secretion, insulin signaling, lipid 
homeostasis  and  disease-related  increases  in  inflammatory  mediators.  The  insulin  responsive 
facilitative glucose transporter GLUT4 is the first molecule to have been identified as a direct target of 
HIV protease inhibitors. Efforts to elucidate the mechanisms directly responsible for the evolution of 
insulin resistance during HIV infection and therapy will be greatly assisted by the further identification 
and  characterization  of  direct  molecular  targets  amenable  to  pharmacologic  therapy  and/or  the 
development of newer antiretroviral agents that do not adversely affect these target proteins. 
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INTRODUCTION 
 
  Among  the  many  metabolic  perturbations  that 
occur  as  a  result  of  HIV  infection  and  its  treatment, 
alterations  in  normal  glucose  homeostasis  remain  a 
particularly prevalent and alarming clinical change in 
affected patients
[1]. Much of this concern is due to the 
recognition  of  the  long-term  complications  of  insulin 
resistance  and  hyperglycemia  as  understood  in  the 
context of the growing worldwide epidemic of type 2 
diabetes  mellitus
[2].  As  a  result,  there  remains 
considerable  interest  in  elucidating  the  molecular 
mechanisms responsible for disordered glucoregulation 
during  highly  active  antiretroviral  therapy  (HAART). 
Goals of current research efforts in this area are many. 
They include the identification of ways to predict those 
patients  at  greatest  risk  for  developing  diabetes,  the 
modification of existing antiviral regimens to minimize 
this  risk  and  the  tailoring  of  diabetes  treatment 
strategies  toward  the  underlying  genetic  and/or 
molecular defects present in these patients. Ultimately, 
the goal is to develop newer antiretroviral agents that 
maintain  their  clinical  efficacy  in  preventing  HIV 
replication without causing their deleterious metabolic 
effects. While progress has been made in defining the 
epidemiology of insulin resistance in the HIV infected 
patient  and  a  clearer  appreciation  of  the  relative 
contributions of each of the components of HAART is 
starting  to  emerge
[3],  significant  gaps  remain  in  our 
understanding  of  the  molecular  basis  of  insulin 
resistance in this setting. 
  In attempting to identify the mediators of impaired 
glucose tolerance during HIV infection, it is important 
to  first  acknowledge  both  the  similarities  and 
differences  in  this  clinical  setting  compared  to  the 
general  population.  The  genetic  and  environmental 
factors present in HIV negative individuals co-exist in 
HIV infected patients and can independently contribute 
to  altered  glucose  homeostasis.  While  poor  nutrition 
and  wasting  were  prevalent  manifestations  of  HIV 
infection  in  the  pre-HAART  era
[4],  the  successful 
containment  of  viral  replication  and  immune 
reconstitution  have  led  to  the  re-emergence  of 
nutritional  excess  as  a  contributing  problem
[5].  This 
generalized  fat  accumulation,  distinct  from  the 
lipodystrophic changes found in the HIV dysmetabolic 
syndrome, is “fueled” by the consumption of the same 
high  fat  diet  and  sedentary  lifestyle  characteristic  of 
western societies. Thus, not all of the increased visceral 
adiposity  observed  may  be  directly  related  to  HIV 
therapies. Type 2 diabetes is also recognized to be a 
polygenetic disease such that relatively small defects in 
multiple  mediators  of  normal  insulin  signaling 
pathways  can  collectively  lead  to  the  overt 
manifestation of impaired glucose tolerance
[6]. In this 
context,  further  perturbations  in  glucoregulation 
induced by HIV infection may lead to clinical changes 
that would not otherwise be apparent. Therefore, while 
it is important to investigate specific mechanisms for 
insulin resistance in HIV infection, the environmental 
and  genetic  setting  in  which  this  occurs  cannot  be 
ignored. This is particularly important in attempting to Am. J. Infect. Dis., 2 (3): 187-192, 2006 
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extrapolate study results to potential effects on insulin 
sensitivity in the developing world. 
  With  this  in  mind,  it  is  apparent  that  there  are 
multiple  factors  related  to  HIV  infection  and  its 
treatment that directly contribute to the development of 
insulin  resistance.  Since  the  goal  is  to  define  precise 
etiologic mechanisms, this review will focus upon the 
putative and established molecular targets influencing 
normal  glucose  metabolism  which  are  altered  during 
HAART.  Any  alteration  in  the  expression  and/or 
activity  of  each  of  these  proteins  has  the  significant 
potential for causing multiple downstream changes in 
affected  pathways.  Compensatory  changes  will  also 
frequently  occur  over  time,  particularly  when  critical 
pathways are perturbed. Therefore, an emphasis will be 
made on acute changes occurring within the timeframe 
of minutes to hours rather than more chronic changes 
occurring over weeks to months. While the significant 
metabolic changes occurring under chronic conditions 
may  overshadow  many  of  these  acute  changes,  it  is 
likely that the greatest chance for establishing the most 
proximate  effects  of  antiretroviral  therapy  on  insulin 
sensitivity  is  to  be  found  by  examining  these  earlier 
timepoints. 
  While  the  fundamental  aspects  of  normal 
glucoregulation have been studied and understood for 
decades, knowledge in this area continues to grow at an 
incredible  pace  within  recent  years
[7].  Notable  is  a 
growing understanding of the role of the adipocyte as 
an  endocrine  organ
[8].  We  are  only  now  starting  to 
identify  and  characterize  the  normal  regulation  and 
function of adipokines such as leptin, adiponectin and 
resistin
[9].  In  addition,  the  molecules  involved  in  the 
distal portions of the insulin signaling pathway are still 
being identified and the intricate relationships between 
many  seemingly  divergent  metabolic  pathways  are 
beginning  to  be  deciphered
[10].  Continued  progress  in 
these areas will certainly aid efforts to understand the 
molecular mechanisms responsible for altered glucose 
homeostasis during HAART.  
  Since regulation of glucose flux is dependent upon 
the  coordinated  action  of  many  tissues,  particular 
attention should be made to the effects of changes in 
candidate  molecular  targets  in  each  of  these  tissues. 
While  defects  in  peripheral  glucose  disposal, 
particularly skeletal muscle, appear to be a predominate 
change observed during HAART
[11], key insights into 
etiologic  mechanisms  and  potential  therapeutic 
solutions can be obtained by also considering effects on 
endogenous glucose production from the liver, insulin 
secretion from the b-cell and the endocrine function of 
adipocytes.  
 
Inflammatory cytokines: Circulating cytokine levels, 
particularly TNF-a and IL-6, are frequently elevated in 
HIV  positive  patients
[12].  Furthermore,  co-morbid 
conditions  associated  with  HIV,  such  as  hepatitis  C 
infection
[13]  also  independently  contribute  to  elevated 
TNF-a levels. It is well established that such elevations 
in TNF-a can cause significant impairment of insulin 
action
[14].  The  molecular  mechanism(s)  by  which 
elevations in TNF-a and other inflammatory cytokines 
lead to insulin resistance is incompletely understood
[15]. 
However,  these  cytokines  can  influence  both  normal 
suppression of hepatic glucose production and insulin 
stimulated  glucose  uptake.  In  addition,  TNF-a  can 
indirectly  influence  peripheral  insulin  sensitivity  by 
stimulating triglyceride and free fatty acid production in 
the liver. 
  Initial  evaluations  of  insulin  sensitivity  in  HIV-
infected  patients,  particularly  in  the  pre-HAART  era, 
suggested that virus infection itself was not sufficient to 
change insulin sensitivity
[16]. In treatment-naïve patients 
with  wasting,  insulin  sensitivity  was  actually 
increased
[4]. However, reflecting the adipocyte’s ability 
to secrete inflammatory cytokines, there appears to be a 
close  link  between  hypersecretion  of  TNF-a  and 
visceral  adiposity  in  the  more  generalized  HIV 
independent metabolic syndrome
[17]. Thus, the additive 
effect of changes in body fat observed during HAART, 
with  increased  cytokine  secretion  from  visceral 
adipocytes  and  elevated  cytokine  production  from 
infection  may  lead  to  sufficient  changes  in  insulin 
sensitivity to produce clinical symptoms
[12]. However, 
the potential magnitude of this contribution relative to 
the effects of antiretroviral therapy is not clear. It was 
not until the widespread introduction of HIV protease 
inhibitors  (PIs)  in  the  late  1990’s  that  the  dramatic 
increase  in  reported  cases  of  altered  glucose 
homeostasis  was  recognized
[18].  Since  PIs  appear  to 
play  a  primary  role  in  the  development  of  HAART 
associated insulin resistance, primary consideration of 
the cellular effects of these drugs will be considered in 
discussing direct molecular targets. 
 
GLUT4:  The  elucidation  of  changes  in  glucose 
transport  in  the  induction  of  peripheral  insulin 
resistance is perhaps one of the clearest examples of the 
utility of focusing efforts on the identification of direct 
targets of antiretroviral drugs. Recent progress in this 
area  has  allowed  the  establishment  of  the  insulin 
responsive facilitative glucose transporter GLUT4 as a 
proximate cause of altered insulin sensitivity. To date, 
this  molecule  remains  the  only  protein  to  have  been 
definitively identified as a direct target of antiretroviral 
therapy.  While  changes  in  the  expression  and/or 
function of other potential target molecules are likely to 
contribute to significant changes in whole-body glucose 
homeostasis,  the  establishment  of  these  proteins  as 
direct mediators, rather than secondary effectors, is still 
largely lacking. Though it remains entirely possible, if 
not likely, that additional drug targets will be identified, 
the experience with GLUT4 can serve as an excellent 
example of the type of research that is still needed to 
fully characterize, prevent and/or treat HIV associated Am. J. Infect. Dis., 2 (3): 187-192, 2006 
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insulin resistance. In addition to the insights that can be 
gained  regarding  the  direct  cellular  effects  of  PI 
therapy, such research efforts are also likely to provide 
valuable  new  clues  to  the  regulatory  mechanisms 
influencing  glucose  levels  in  normal  and  HIV-
independent diseased states. 
  The initial observation that established GLUT4 as a 
candidate molecular target of PIs was the finding that 
indinavir acutely (i.e. within minutes) inhibits insulin-
stimulated  glucose  uptake  into  3T3-L1  adipocytes
[19]. 
Furthermore,  it  was  found  that  this  inhibition  occurs 
without any detectable changes in GLUT4 translocation 
to the plasma membrane and can be induced with drug 
addition following maximal insulin stimulation. These 
results clearly differ from later reports that have shown 
that  under  chronic  conditions,  PIs  can  affect  insulin 
signaling
[20]. Importantly, inhibition of glucose uptake 
is also observed in a heterologous GLUT4 expression 
system that is not insulin responsive
[19]. While the drug 
concentrations used in initial experiments far exceeded 
the  PI  levels  typically  achieved  during  HAART, 
subsequent studies in primary rat adipocytes confirmed 
that  the  acute  effect  on  GLUT4  activity  is 
pharmacologically relevant
[21].  
  To link these in vitro findings to effects on whole 
body  glucose  homeostasis,  hyperinsulinemic 
euglycemic clamps, the gold standard test for peripheral 
insulin sensitivity, were performed on healthy rodents 
following acute exposure to indinavir
[22]. As predicted, 
significant insulin resistance was observed immediately 
following the administration of the PI and full insulin 
sensitivity  could  be  restored  following  drug  removal. 
Supporting  a  direct  link  between  these  laboratory 
findings  and  clinically  relevant  drug  effects,  it  was 
found that a single dose of indinavir to HIV negative 
healthy volunteers was sufficient to induce peripheral 
insulin  resistance
[23].  Importantly,  these  changes  were 
observed without any of the other associated features of 
the HIV dysmetabolic syndrome.  
  While these studies have established that GLUT4 
inhibition is a primary mechanism by which indinavir 
acutely  induces  insulin  resistance,  attempts  to 
extrapolate  these  findings  to  other  PIs  has  been  less 
clear. Clinically, indinavir appears to be the most potent 
of  the  PIs  in  inducing  significant  changes  in  insulin 
sensitivity.  Other  PIs,  such  as  amprenavir,  do  not 
appear  to  be  as  effective  in  causing  acute  insulin 
resistance
[24]. Thus, it has been proposed that GLUT4 
inhibition represents a drug specific effect rather than a 
general  effect  of  all  PIs.  This  contrasts  with  the 
observation  that  GLUT4  inhibition  in  vitro  can  be 
produced  with  nearly  all  of  the  currently  available 
PIs
[19]. Since the Kis for GLUT4 inhibition for the PIs 
are  all  in  the  low  micromolar  range  (unpublished 
observations),  it  is  possible  that  the  apparent 
discrepancy between the observed in vitro and in vivo 
effects of the PIs is primarily related to differences in 
the  peak  levels  of  bioavailable  drug  achieved  during 
clinical  use.  In  general,  PIs  are  highly  hydrophobic 
compounds with a significant degree of protein binding 
in  serum.  Since  indinavir  has  the  least  amount  of 
protein binding, it is not surprising that this PI is the 
most potent inducer of insulin resistance in vivo.  
  A notable exception to the above generalization is 
the newest PI atazanavir, which has not been found to 
be associated  with acute insulin resistance  in vivo
[25]. 
Out of all of the available PIs, atazanavir is the only 
drug to have no observable effects on in vitro glucose 
transport  activity
[26].  In  consideration  of  the  GLUT4 
inhibitory  properties  of  candidate  PIs  together  with 
protein binding capacity and the necessary drug levels 
achieved  during  clinical  use,  the  above  data  indicate 
that a simple in vitro assay for acute effects on insulin 
stimulated  glucose  uptake  can  reasonably  predict  the 
potential  to  induce  acute  insulin  resistance  in  treated 
patients.  
  Nevertheless,  while  potentially  valuable  in  large 
screening  trials  of  drugs  in  development,  such 
information does not provide a useful method to design 
and  develop  newer  generations  of  PIs,  one  of  the 
primary goals of research in this area. However, with 
identification  of  a  relevant  molecular  target,  it  now 
becomes  possible  to  investigate  the  precise  structural 
basis  for  the  adverse  metabolic  effect  in  relation  to 
changes in the desired beneficial effect in controlling 
HIV  replication.  Such  structurally  based  studies  with 
GLUT4  are  now  in  progress.  Recent  work  has 
established  that  the  core  peptidomimetic  structure 
within  PIs  is  necessary  for  GLUT4  inhibition  and 
affinity labeling studies have confirmed that the adverse 
effect on glucose uptake is due to direct binding of PIs 
to this transporter
[27].  
 
GLUT2:  In  addition  to  inducing  peripheral  insulin 
resistance,  PIs  have  also  been  found  to  contribute  to 
impaired insulin release from b-cells, which increases 
the risk of patients to develop overt diabetes mellitus
[11]. 
Again, in vitro studies have provided insights into the 
molecular  mechanism(s)  for  impaired  glucose 
stimulated insulin release  from these cells. While the 
direct molecular targets for PIs in these cells has not yet 
been  established,  defective  glucose  transport  and/or 
metabolism has been implicated
[28]. Thus, it is possible 
that  the  effects  on  b-cell  function  are  due  in  part  to 
acute  changes  in  the  function  of  the  related  glucose 
transporter(s)  present  in  this  tissue,  namely  GLUT2. 
This  molecule,  which  is  expressed  in  both  the  b-cell 
and liver, has a Km for glucose which is well within the 
physiologic  range  of  serum  glucose  levels.  For  this 
reason, this protein has been proposed to function as a 
glucose sensor in these tissues. In addition to effects on 
insulin  secretion,  PIs  have  been  found  to  have  acute 
effects  on  glycogen  synthesis  in  cultured 
hepatocytes
[29].  It  remains  to  be  determined  whether 
altered glucose transport is contributing to this effect. Am. J. Infect. Dis., 2 (3): 187-192, 2006 
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  Similar to the differences in acute versus chronic 
effects on peripheral glucose disposal, the effects of PIs 
on  b-cell  function  can  be  strongly  influenced  by  the 
timeframe in which studies are performed. In contrast 
to the acute effects of PIs on glucose-stimulated insulin 
release, more chronic exposure to PIs appears to alter 
insulin signaling with clear differences between PIs
[30]. 
Whether this is the result of direct alterations on other 
protein targets or secondary changes following glucose 
transport inhibition remains to be determined. 
 
Free fatty acids: Since increased incidence of insulin 
resistance  during  HAART  was  first  identified  in 
conjunction  with  other  metabolic  changes,  namely 
lipodystrophy  and  hyperlipidemia,  it  was  initially 
believed  that  decreased  insulin  sensitivity  was 
secondary to these chronic changes. However, it is now 
clear that PIs have direct effects on insulin sensitivity 
that  are  independent  from  the  lipodystrophic  and/or 
hyperlipedemic changes
[31]. Increases in free fatty acid 
levels, whether directly or indirectly resulting from PI 
use, can contribute to altered glucose homeostasis, both 
through toxic effects on peripheral insulin signaling
[32] 
and impaired b-cell responsiveness
[33].  
  Recent in vitro studies have linked the use of PIs to 
alterations  in  the  expression  and/or  processing  of  the 
sterol  response  element  binding  protein  SREBP-
1c
[20,34]. This protein normally regulates the expression 
of several genes important in fatty acid synthesis. While 
speculation has been made regarding the role of altered 
SREBP  processing  in  the  evolution  of  lipodystrophic 
changes  through  effects  on  adipocytes  differentiation, 
this molecule may also have more direct influences on 
insulin sensitivity through acute changes in intracellular 
lipid levels. The relative rapidity in which changes can 
be observed in vitro makes this molecule attractive as a 
direct  target  of  PIs.  Nevertheless,  it  has  yet  to  be 
established  whether  PIs  have  any  direct  association 
with  the  SREBP  or  the  molecules  affecting  its 
processing. Since SREBP activity is strongly correlated 
with nutritional status, it is possible that these changes 
reflect changes in cellular energy, perhaps secondary to 
effects  on  glucose  flux.  Attempts  to  more  carefully 
delineate  whether  SREBP-1c  changes  are  primary 
versus secondary cellular effects will greatly facilitate 
efforts  to  determine  the  role  of  this  protein  in  the 
development of insulin resistance.  
 
Leptin:  Increased  interest  in  the  potential  role  of 
altered  adipokine  secretion  during  HAART  has 
coincided with the growing recognition of the role of 
these  hormones  in  normal  glucose  homeostasis
[35]. 
Leptin,  one  of  the  earliest  of  the  adipocyte-secreted 
hormones to be identified, has been characterized as a 
regulator of total body fat mass via central effects on 
appetite  in  the  hypothalamus.  This  hormone  also 
appears to have significant effects on peripheral insulin 
sensitivity. The administration of leptin to patients with 
congenital  generalized  lipodystrophy  leads  to  a  rapid 
and  dramatic  improvement  in  peripheral  insulin 
sensitivity
[36]. Exogenous leptin has also been shown to 
ameliorate  hyperlipidemic and lipodystrophic changes 
in PI-treated mice
[37]. 
  Given  the  close  association  between  adipocyte 
mass and leptin levels, it is not surprising that leptin 
levels  are  correlated  with  lipodystrophic  changes  in 
HIV infected patients
[38]. However, leptin levels do not 
appear  to  correlate  with  insulin  resistance  in  this 
lipodystrophic  patient  population.  Despite  the 
likelihood that changes in leptin levels are secondary to 
changes in body fat, it remains possible that more direct 
effects of PIs on leptin expression and/or secretion also 
may occur on a more acute timescale. Insulin signaling 
is  known  to  directly  stimulate  leptin  secretion
[39]. 
Furthermore, inhibition of glucose transport with either 
cytochalasin  b  and/or  phloretin  can  reduce  leptin 
secretion from cultured adipocytes
[40]. Thus, it is again 
possible  that  the  direct  inhibition  of  GLUT4  activity 
induced  by  PIs  secondarily  leads  to  changes  in 
adipocyte leptin expression, even before lipodystrophic 
changes occur.  
 
Adiponectin:  The  novel  adipocyte-secreted  hormone 
adiponectin also is known to significantly affect whole 
body glucose homeostasis, both by enhancing hepatic 
insulin action and peripheral insulin sensitivity
[41]. The 
correlative  link  between  reductions  in  adiponectin 
levels  and  HIV-associated  lipodystrophy  has 
established  this  hormone  as  a  potential  mediator  of 
insulin resistance in affected patients
[42,43]. While it is 
possible that these changes are again merely secondary 
to changes in body fat, recent studies have shown that 
PIs can produce relatively acute dose-related reductions 
adiponectin levels in vitro and in vivo
[44]. Within this 
mouse model system, ritonavir and adiponectin did not 
significantly  alter  indirect  measures  of  insulin 
sensitivity.  However,  exogenous  adiponectin 
administration was found to reverse the hyperlipidemia 
induced by ritonavir treatment.  
  Complicating the interpretation of the significance 
of  these  findings,  a  recent  study  has  reported  that 
treatment  of  healthy  HIV  negative  subjects  with  PIs 
increases,  rather  than  decreases  adiponectin  levels
[45]. 
Given  the  apparent  complexity  of  glucose  regulatory 
pathways, it is possible that with longer periods of drug 
exposure,  compensatory  mechanisms  are  stimulated, 
masking or abrogating changes directly induced by the 
drugs.  Further  studies  are  still  needed  to  explore  the 
direct  molecular  mechanism  by  which  PIs  alter 
adiponectin expression and/or secretion.  
 
CONCLUSION 
 
  The problem of identifying and characterizing the 
molecular mechanisms for altered glucose homeostasis 
during  HIV  infection  has  proven  to  be  a  challenging Am. J. Infect. Dis., 2 (3): 187-192, 2006 
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task for both basic scientists and clinicians alike. Due to 
the large number of clinical variables involved and the 
complexity of the signaling pathways that participate in 
glucoregulation,  attempts  to  address  the  problem  in 
clinical trials have thus far been met with only limited 
success. While such studies have generated a large (and 
growing) list of potential mediators, the investigation of 
acute changes in the expression and/or function of these 
molecules in vitro and within controlled animal model 
systems  has  the  potential  to  provide  valuable 
mechanistic  information  to  guide  the  development  of 
safer HIV treatment regimens. A better knowledge and 
appreciation  for  the  most  proximate  changes  in  the 
molecules controlling insulin sensitivity resulting from 
HIV  infection  and  treatment  will  provide  a  crucial 
framework  for  the  further  dissection  of  the  complex 
relationships between affected pathways.  
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